Compare HNI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNI | TARS |
|---|---|---|
| Founded | 1944 | 2016 |
| Country | United States | United States |
| Employees | 19500 | N/A |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 1994 | 2020 |
| Metric | HNI | TARS |
|---|---|---|
| Price | $37.21 | $61.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $70.00 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 574.4K | 413.4K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $2,839,000,000.00 | $451,360,000.00 |
| Revenue This Year | $117.19 | $56.43 |
| Revenue Next Year | $3.68 | $30.19 |
| P/E Ratio | $33.38 | ★ N/A |
| Revenue Growth | 12.37 | ★ 146.71 |
| 52 Week Low | $31.41 | $38.51 |
| 52 Week High | $53.29 | $85.25 |
| Indicator | HNI | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 29.93 |
| Support Level | $33.72 | $38.85 |
| Resistance Level | $47.09 | $76.47 |
| Average True Range (ATR) | 1.14 | 3.11 |
| MACD | 0.70 | -1.04 |
| Stochastic Oscillator | 80.32 | 5.17 |
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.